AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03477019 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.
Study NCT03477019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SonoVue
Description: consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol.
Study NCT03477019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
Study NCT01092078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINT
Description: Motivational interviewing for lifestyle changes associated with treating hypertension
Study NCT01092078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigation for colonoscopy.
Study NCT04462471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: I-124 PET/CT lesion dosimetry
Description: I-124 PET/CT scans will be performed during this process to quantify baseline RAI avidity in index metastatic lesion(s)
Study NCT04462471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Dose level 1 \& 2: 960 mg PO bid Dose level -1: 720 mg PO bid Dose level -2: 480 mg PO bid
Study NCT04462471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Dose level 2: 60 mg IV weekly Dose level 1, -1, -2: 45 mg IV weekly
Study NCT03575871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 100 mg
Description: PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03575871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842 200 mg
Description: PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03575871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, administered as two tablets to be taken orally once daily for 12 weeks
Study NCT03232099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Wine consumption
Description: After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
Study NCT03232099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period without alcohol consumption
Description: After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
Study NCT03780946 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic anastomosis for pancreaticojejunostomy
Description: Magnetic anastomosis for pancreaticojejunostomy
Study NCT03780946 — intervention group
Intervention type: PROCEDURE
Intervention: Traditional hand-sewn anastomosis
Description: Traditional manual anastomosis for pancreaticojejunostomy
Study NCT01825135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Study NCT01825135 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: sham stimulation will be applied to the quadriceps
Study NCT02276079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 - 0.7 × age).
Study NCT02276079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Aerobic Exercise
Description: Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
Study NCT01613547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days
Study NCT01392053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbosacral Massage
Description: Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
Study NCT01327872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, fasted
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
Study NCT05223933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive community case management
Description: CHWs in the intervention arm conducted door-to-door fever screening for all inhabitants of all consenting households in their catchment area every fortnight. All individuals with temperature ≥ 37.5°C or history of self-reported fever in the previous two weeks were tested with an RDT; positive individuals who were not pregnant and did not have signs of severe disease were treated with artesunate-amodiaquine according to treatment guidelines. Individuals identified as requiring a referral during Pro-CCM visits were assisted with transfer to the healthcare center, with transportation handled by the project staff.
Study NCT00807729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
Study NCT00807729 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LapCBDE
Description: LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
Study NCT03386448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine and naltrexone
Description: participants will receive scopolamine and naltrexone in buccal drops
Study NCT03386448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo arm
Description: participants will receive placebo medications
Study NCT01918436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAMS intervention
Description: In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
Study NCT01918436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
Study NCT01327872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, with food
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
Study NCT03840798 — intervention group
Intervention type: OTHER
Intervention: Child Abuse Clinical Decision Support system
Description: The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~1. a universal child abuse screen (CAS)~2. an embedded child abuse alert system~3. alerts to physicians and advanced practice providers~4. physical abuse order sets
Study NCT01327872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40mg 2 x 20-mg tablets, orally, fasted
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
Study NCT00879060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: spironolactone 50mg daily
Study NCT01223430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Si-Ni-Tang/ Placebo of Si-Ni-Tang
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
Study NCT01223430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Si-Ni-Tang/ Placebo of Si-Ni-Tang
Description: The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal \< 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
Study NCT02420171 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adding insulin to In Vitro culture media
Description: We will add insulin for in vitro culture of human embryos
Study NCT01323283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3
Description: This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
Study NCT01323283 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: transdermal gel, 75 mg daily
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colecalciferol
Description: drink solution, 24000 IU once per month
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink solution
Description: drink solution, 0 IU Colecalciferol once per month
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo drink solution
Description: drink solution, 0 IU Colecalciferol once per month
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal gel
Description: transdermal gel, 0 mg testosterone daily
Study NCT02419105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo transdermal gel
Description: transdermal gel, 0 mg testosterone daily
Study NCT00552565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular 15mg
Description: Oral Tablets
Study NCT00552565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00552565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular
Description: Rezular 37.5mg 3xday up to 12 weeks
Study NCT00552565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezular
Description: Rezular 75mg 3xday up to 12 weeks
Study NCT03789474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HUNTLEIGH FLOWTRON ACS900
Study NCT02929667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Standard 6 weeks titration, starting 10 mg per day.
Study NCT02929667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard 6 weeks titration.
Study NCT00259337 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine
Description: 0.5 mL, IM
Study NCT02544360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photoaging mobile app promoting poster campaign.
Description: Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie).
Study NCT03708081 — intervention group
Intervention type: PROCEDURE
Intervention: ProTaper Next
Description: Root canal instrument
Study NCT03708081 — intervention group
Intervention type: PROCEDURE
Intervention: TF Adaptive
Description: Root canal instrument
Study NCT03634657 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Plain X-ray protection shield
Description: Coronary angiography with mere X-ray protection shield
Study NCT03634657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protection shield & X-ray protective strips
Description: Coronary angiography with X-ray protection shield \& X-ray protective strips
Study NCT03634657 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protection shield & protective strips & patient cut-outs
Description: Coronary angiography with X-ray protection shield \& X-ray protective strips \& X-ray protection patient cut-outs
Study NCT01064310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral anti-angiogenic treatment
Study NCT01064310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: oral anti-angiogenic treatment
Study NCT01327872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501 40 mg 2 x 20-mg tablets, orally, with food
Description: single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
Study NCT02496585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Study NCT00879060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: inactive placebo pill daily
Study NCT02496585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT04042675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: observational study
Description: There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
Study NCT02496585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01826877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdGMCAIX-transduced autologous dendritic cells
Description: Given ID
Study NCT00694694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin + artesunate
Description: Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
Study NCT01826877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given ID
Study NCT01826877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02425020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat Protein
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Study NCT02425020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Study NCT02425020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate
Description: Immediately (\<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
Study NCT00679432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
Study NCT00679432 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
Study NCT00694694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days
Study NCT00679432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
Study NCT00679432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-MMX® 6 mg
Description: 6 mg/day, 6 mg tablets
Study NCT00679432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide-MMX® 9 mg
Description: 9 mg/day, 9 mg tablets
Study NCT00679432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00679432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asacol® 400 mg
Description: 2400 mg/day, 400 mg tablets
Study NCT02657369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg
Study NCT02201485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Study NCT02201485 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon
Study NCT01841788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Adhesion Patch
Study NCT01841788 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Thermal Adhesion Patch
Study NCT01841788 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Study NCT01040975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based intervention targeting MD communication; Summary Report
Description: Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
Study NCT02308605 — intervention group
Intervention type: DEVICE
Intervention: SMARTCap
Description: The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
Study NCT02562534 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI compatible ElectroCardioGraph
Description: MRI with ECG control for people with healthy heart or heart diseases
Study NCT00598169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375mg/m2 on Day 1